CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 179 enrolled
Drug / intervention
Nepicastat +1 moredrug
Likely dose
Nepicastat 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01704196
NCT01704196Phase 2Completed
CompareCT.gov

Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of Nepicastat for Cocaine Dependence

National Institute on Drug Abuse (NIDA)·interventional·Posted Oct 11, 2012·Updated May 18, 2017

In Brief

A Phase 2 clinical trial evaluating Nepicastat and Placebo for Cocaine Dependence. Completed, enrolled 179 participants across 10 sites.

Detailed Summary

The objective of this study is to evaluate the safety and efficacy of Nepicastat in improving the number of subjects that achieve abstinence from cocaine and reducing cocaine use in subjects with cocaine dependence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Dependence
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 11, 2012
Enrollment StartApr 1, 2013
Primary CompletionAug 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.7 years ago

Interventions

Nepicastatdrug

120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.

Placebodrug